Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally
Authors:
- 8 June 2009
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 11 (8) , 718-728
Abstract
Background: The poor prognosis associated with ovarian cancer is primarily the result of delayed diagnosis and the lack of an effective treatment for advanced disease. Use of novel immunotherapy strategies are being evaluated that work to enhance local and systemic immune responses against cancer cells and can possibly work together with traditional cytotoxic chemotherapy regimens to produce more effective treatment options.Methods: In the present study, we describe a gene‐based therapy whereby the anticancer cytokine interleukin‐12 gene (pmIL‐12) is formulated with a synthetic polymeric delivery vehicle (PPC) and administered intraperitoneally into a mouse model of disseminated ovarian cancer.Results: The administration of pmIL‐12/PPC in tumor‐bearing mice was associated with a shift towards a Th1 immune state, including significant increases in murine IL‐12 (mIL‐12) and interferon (IFN)‐γ (mIFN‐γ) in ascites fluid, with little change in systemic levels of these proteins. The mIL‐12 protein was detectable for several days and could be reintroduced with subsequent injections. We show that treatment delayed the onset of ascites formation and improved survival in a dose‐dependent manner. A significant decrease in vascular endothelial growth factor was associated with pmIL‐12/PPC delivery and believed to play a predominant role in inhibiting ascites accumulation. Administration of pmIL‐12/PPC was associated with minimal toxicity and, when combined with standard chemotherapies, resulted in additive improvement in survival.Conclusions: Taken together, these results suggest that pmIL‐12/PPC may be an effective strategy for inhibiting progression of disseminated ovarian cancer and may offer a new option for treatment of advanced disease that can be used to complement standard therapies. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinomaJournal of Translational Medicine, 2007
- Immunotherapy of cancer by IL-12-based cytokine combinationsExpert Opinion on Biological Therapy, 2007
- Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial CellsCancer Research, 2007
- Post-Chemotherapeutic Administration of Interleukin-12 Retards Tumor Growth and Enhances Immune Cell Function: Combination Therapy Using Paclitaxel and IL-12Cancer Investigation, 2006
- Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patientsInternational Journal of Gynecological Cancer, 2006
- Safety of Interleukin-12 Gene Therapy Against Cancer: A Murine Biodistribution and Toxicity StudyHuman Gene Therapy, 2003
- Hepatotoxicity of ChemotherapyThe Oncologist, 2001
- Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell CarcinomaJournal of Interferon & Cytokine Research, 2001
- Interleukin 12 Gene Transfer into Skin Distant from the Tumor Site Elicits Antimetastatic Effects Equivalent to Local Gene TransferHuman Gene Therapy, 2001
- Interleukin-12 Overcomes Paclitaxel-Mediated Suppression of T-Cell ProliferationImmunopharmacology and Immunotoxicology, 1998